---
title: 'Low &amp; Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS
  (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm,
  biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant,
  grade 2/3 glioma'
date: '2025-02-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39929517/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250211171020&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'INTRODUCTION: All grade 2/3 gliomas are incurable and at the time of
  inevitable relapse, patients have significant unmet needs with few effective treatments.
  This study aims to improve outcomes by molecular profiling of patients at relapse,
  then matching them with the best available drug based on their molecular profile,
  maximising the chances of patient benefit while simultaneously testing multiple
  novel ...'
disable_comments: true
---
INTRODUCTION: All grade 2/3 gliomas are incurable and at the time of inevitable relapse, patients have significant unmet needs with few effective treatments. This study aims to improve outcomes by molecular profiling of patients at relapse, then matching them with the best available drug based on their molecular profile, maximising the chances of patient benefit while simultaneously testing multiple novel ...